Active Biotech AB Interim report January – March 2012

* Laquinimod – submission of application for regulatory approval in the EU planned for second half of 2012
                 – Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN)
* TASQ        – a Phase I investigator-sponsored clinical trial is under way 
                 – enrolment of patients to Phase III study proceeding according to schedule
* ANYARA     – Phase III trial continuing according to plan
* 57-57          – a clinical trial in systemic sclerosis/scleroderma in progress
* ISI               – project is proceeding as planned
* Net sales SEK 2.6 M (2.7)
* Operating loss SEK 100.7 M (loss: 70.9)
* Net loss SEK 99.0 M (loss: 69.3 )
* Loss per share for the period was SEK 1.44 (loss: 1.02)
  

For further information, please contact: